Twinbeech Capital LP Biomarin Pharmaceutical Inc Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $5.01 Million - $6.72 Million	-61,870 Reduced 38.21%	100,053 $10.4 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $13.3 Million - $15.7 Million	161,923 New	161,923 $13.7 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $1.2 Million - $1.35 Million	-15,874 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $665,097 - $807,141	8,900 Added 127.62%	15,874 $1.2 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $506,382 - $629,054	6,974 New	6,974 $612,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.